Links to prescribing information and adverse event reporting information can be found at the bottom of the page. For UK Healthcare professionals only.
These NHS service evaluations found potential chair time and capacity savings when treating RAS wild-type mCRC patients with vectibix instead of cetuximab in combination with chemotherapy.1-3
Request support
Get in touch with the Amgen team who will assist with your enquiry.
References
- Cortez L, Neill W, Southam S. A Service evaluation of capacity use (chair and treatment time) for metastatic colorectal cancer patients (mCRC) treated with EGFR therapies and chemotherapy at The Royal Marsden NHS Foundation Trust. J Oncol Pharm Practice. 2022;28:40–1(suppl 2). Abstract 43.
- Lau E & Neill W. Presentation at the 25th Annual BOPA Symposia, 7-9 October 2022.
- Case A, Adams, Arif S. Presentation at ESMO 21st World Congress on Gastrointestinal Cancer, 3-6 July 2019.